| 发明名称 | Suspension formulations | ||
| 摘要 | The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurized metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation. | ||
| 申请公布号 | US9011923(B2) | 申请公布日期 | 2015.04.21 |
| 申请号 | US200912865142 | 申请日期 | 2009.02.02 |
| 申请人 | Innovata Biomed Limited;Vectura Limited | 发明人 | Lewis David Andrew;Keeble Christina Alexandra;Whitfield Nicola Kim;Church Tanya |
| 分类号 | A61K9/50;A61K9/12;A61P11/08;A61P11/06;B29B9/16;A61K31/00;A61K31/167;A61K31/58;A61K9/00 | 主分类号 | A61K9/50 |
| 代理机构 | LeClairRyan, a Professional Corporation | 代理人 | LeClairRyan, a Professional Corporation |
| 主权项 | 1. A suspension formulation comprising: particles comprising a pharmaceutically active agent, wherein the pharmaceutically active agent is tiotropium; a propellant; and trehalose and leucine as suspension stabilisers, wherein the composition comprises an amount of trehalose of 0.0003 to 0.02% by weight of the formulation. | ||
| 地址 | Edinburgh GB | ||